Alphamab converts CRO platform into drug development engine
By Marie Powers
Friday, July 11, 2014
Suzhou Alphamab Co. Ltd. is among the new generation of Chinese biopharmas moving rapidly along the evolutionary curve from contract research activities to the construction of a pipeline of biosimilars.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.